PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Nicola Tinari(University of Chieti-Pescara), Laura Iezzi(Ospedale SS. Annunziata), Paola Scavina(Azienda Ospedaliera San Giovanni Addolorata), Olivia Bacciu, Rossana Berardi(Marche Polytechnic University), Luca Moscetti(Ospedale di Belcolle), Corrado Ficorella(University of L'Aquila), Enzo Veltri(Ospedale Santa Maria Goretti), Agnese Fabbri(Ospedale di Belcolle), Beatrice Taurelli Salimbeni(European Institute of Oncology), Andrea Botticelli(Policlinico Umberto I), Clara Natoli(Kliniken Essen-Mitte), Katia Cannita(Ospedale San Giuseppe), Emilio Bria(Università Cattolica del Sacro Cuore), Ida Paris(Agostino Gemelli University Polyclinic), Andrea Michelotti(Ospedale Santa Chiara), E. Capomolla(Istituti di Ricovero e Cura a Carattere Scientifico), Teresa Gamucci, Giacomo Barchiesi(Sapienza University of Rome), Enzo Maria Ruggeri, Nello Salesi(Tumori Foundation), Lorenzo Livi(European Society for Sexual Medicine), Emanuela Risi(Unknown), Eriseld Krasniqi(National Cancer Institute), Luca Marchetti(Fatebenefratelli Hospital), Domenico Corsi(Ospedale San Carlo), Francesca Sofia Di Lisa, Giuseppe Tonini(Campus Bio Medico University Hospital), Marco Mazzotta(Ospedale Sandro Pertini), Daniele Marinelli(London Cancer), Giuliana D’Auria(Ospedale di Belcolle), Maddalena Barba(National Cancer Institute), Valentina Sini(Ospedale di Santo Spirito), Giuseppina Sarobba(Associazione Istituzione Libera Università Nuorese), Isabella Sperduti(San Gallicano Hospital), Nicola D’Ostilio(Bassano Bresciano Astronomical Observatory), Federica Tomao(Sapienza University of Rome), Francesco Giotta(Istituto Tumori Bari), Mirco Pistelli(Ospedali Riuniti Umberto I), Rosa Saltarelli, Alessandra Cassano, Antonio Russo(University of Palermo), Icro Meattini(Azienda Ospedaliero-Universitaria Careggi), Maria Mauri, Anna Ceribelli(St. Eugenio Hospital), Mauro Minelli, Lucia Mentuccia(Accademia di Belle Arti di Frosinone), Mimma Raffaele(ASL Roma), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 10
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830